ALDX
Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.85M) | (55.85M) | (37.54M) | (62.02M) | (57.78M) | (37.55M) | (60.83M) | (38.89M) | (22.34M) | (18.70M) | (12.09M) | (5.19M) |
| EPS | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.36 |
| Free Cash Flow | (33.35M) | (43.21M) | (30.33M) | (56.65M) | (42.56M) | (37.49M) | (44.99M) | (30.12M) | (19.25M) | (15.16M) | (9.40M) | (4.79M) |
| FCF / Share | -0.56 | -0.73 | -0.51 | -0.97 | -0.79 | -1.10 | -1.66 | -1.39 | -1.21 | -1.34 | -1.09 | -1.25 |
| Operating CF | (33.35M) | (43.21M) | (30.33M) | (56.64M) | (42.56M) | (37.49M) | (44.98M) | (29.86M) | (19.22M) | (15.15M) | (9.31M) | (4.78M) |
| Total Assets | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M | 83.35M | 75.52M | 95.09M | 44.17M | 25.19M | 28.20M | 8.79M |
| Total Debt | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M | 15.33M | 14.75M | 0 | 1.34M | 1.32M | 1.29M | 1.25M |
| Cash & Equiv | 70.04M | 54.53M | 142.82M | 144.42M | 229.79M | 77.86M | 44.43M | 47.36M | 20.02M | 12.02M | 14.65M | 8.53M |
| Book Value | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M | 59.51M | 48.08M | 86.62M | 39.60M | 21.65M | 24.88M | 6.28M |
| Return on Equity | -0.76 | -0.79 | -0.31 | -0.41 | -0.28 | -0.63 | -1.27 | -0.45 | -0.56 | -0.86 | -0.49 | -0.83 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (3.45M) | (6.46M) | (7.69M) | (9.77M) | (9.93M) | (15.81M) | (15.11M) | (16.85M) | (8.08M) | (4.75M) | (8.19M) | (8.99M) |
| EPS | -0.06 | -0.11 | -0.13 | -0.16 | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 | -0.14 | -0.15 |
| Free Cash Flow | (5.11M) | (5.30M) | (7.02M) | (8.56M) | (12.47M) | (12.04M) | (7.97M) | (13.22M) | (9.97M) | 500,440 | (8.02M) | (13.36M) |
| FCF / Share | -0.08 | -0.09 | -0.12 | -0.14 | -0.21 | -0.20 | -0.13 | -0.22 | -0.17 | 0.01 | -0.14 | -0.23 |
| Operating CF | (5.11M) | (5.30M) | (7.02M) | (8.56M) | (12.47M) | (12.04M) | (7.97M) | (13.22M) | (9.97M) | 500,440 | (8.02M) | (13.36M) |
| Total Assets | 66.48M | 72.06M | 77.80M | 84.96M | 93.20M | 104.61M | 117.32M | 126.04M | 141.30M | 148.33M | 147.28M | 155.62M |
| Total Debt | 15.51M | 15.53M | 15.54M | 15.56M | 15.57M | 15.30M | 15.61M | 15.64M | 15.66M | 15.66M | 16.18M | 16.15M |
| Cash & Equiv | 65.00M | 70.04M | 59.34M | 41.24M | 50.35M | 54.53M | 68.12M | 71.03M | 102.49M | 142.82M | 143.33M | 151.68M |
| Book Value | 42.16M | 44.25M | 49.24M | 55.29M | 63.60M | 71.00M | 85.10M | 98.31M | 113.42M | 119.80M | 123.01M | 129.88M |
| Return on Equity | -0.08 | -0.15 | -0.16 | -0.18 | -0.16 | -0.22 | -0.18 | -0.17 | -0.07 | -0.04 | -0.07 | -0.07 |
